DK1504764T3 - Behandling af leverfibrose med antistoffer mod alfa-V-beta-6-integrin - Google Patents

Behandling af leverfibrose med antistoffer mod alfa-V-beta-6-integrin

Info

Publication number
DK1504764T3
DK1504764T3 DK04022921T DK04022921T DK1504764T3 DK 1504764 T3 DK1504764 T3 DK 1504764T3 DK 04022921 T DK04022921 T DK 04022921T DK 04022921 T DK04022921 T DK 04022921T DK 1504764 T3 DK1504764 T3 DK 1504764T3
Authority
DK
Denmark
Prior art keywords
integrin
antibodies
beta
alpha
treatment
Prior art date
Application number
DK04022921T
Other languages
Danish (da)
English (en)
Inventor
Xiaozhu Huang
Dean Sheppard
Robert Pytela
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK1504764T3 publication Critical patent/DK1504764T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK04022921T 1997-08-08 1998-08-07 Behandling af leverfibrose med antistoffer mod alfa-V-beta-6-integrin DK1504764T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5506097P 1997-08-08 1997-08-08
PCT/US1998/016439 WO1999007405A1 (en) 1997-08-08 1998-08-07 TREATMENT OF ACUTE LUNG INJURY AND FIBROSIS WITH ANTAGONISTS OF αvβ6

Publications (1)

Publication Number Publication Date
DK1504764T3 true DK1504764T3 (da) 2008-11-17

Family

ID=21995323

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04022921T DK1504764T3 (da) 1997-08-08 1998-08-07 Behandling af leverfibrose med antistoffer mod alfa-V-beta-6-integrin
DK08004714.5T DK1930022T3 (da) 1997-08-08 1998-08-07 Behandling af blærefibrose med antistoffer mod alfa-V-beta-6-integrin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK08004714.5T DK1930022T3 (da) 1997-08-08 1998-08-07 Behandling af blærefibrose med antistoffer mod alfa-V-beta-6-integrin

Country Status (23)

Country Link
US (5) US20020004482A1 (de)
EP (3) EP0996460B1 (de)
JP (2) JP2001513333A (de)
KR (1) KR100586202B1 (de)
CN (1) CN1267224A (de)
AT (3) ATE286742T1 (de)
AU (1) AU739283B2 (de)
BR (1) BR9814040A (de)
CA (1) CA2297736A1 (de)
CY (2) CY1110462T1 (de)
CZ (1) CZ299768B6 (de)
DE (2) DE69840113D1 (de)
DK (2) DK1504764T3 (de)
EE (1) EE04752B1 (de)
ES (3) ES2235350T3 (de)
HU (1) HU228900B1 (de)
IL (2) IL134288A0 (de)
NZ (2) NZ502546A (de)
PL (2) PL199014B1 (de)
PT (3) PT1504764E (de)
RU (1) RU2221589C2 (de)
TR (2) TR200000374T2 (de)
WO (1) WO1999007405A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) * 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
US20020004482A1 (en) * 1997-08-08 2002-01-10 Xiaozhu Huang Treatment of acute lung injury and fibrosis with antagonists of avbeta6
NZ541431A (en) * 1999-04-22 2008-01-31 Biogen Idec Inc Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
DE19929410A1 (de) * 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
ATE409047T1 (de) * 2001-04-30 2008-10-15 Lilly Co Eli Humanisierte antikörper
EP2287199B1 (de) * 2002-03-13 2017-08-02 Biogen MA Inc. Anti-Alpha V Beta 6 Antikörper
JP2006506323A (ja) * 2002-04-12 2006-02-23 レイヴェン バイオテクノロジーズ， インコーポレイテッド インテグリンα−ｖ−β−６に結合する抗体およびその使用方法
EP1734996B1 (de) * 2004-04-02 2013-05-22 The Regents of The University of California Verfahren und zusammensetzungen für die behandlung und vorbeugung von mit alpha v beta 5-integrin assoziierten krankheiten
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
KR20090027241A (ko) 2006-07-10 2009-03-16 바이오겐 아이덱 엠에이 인코포레이티드 Ｓｍａｄ４-결핍 암의 성장을 억제하기 위한 조성물 및 방법
CN101553505B (zh) * 2006-08-03 2013-07-17 阿斯利康(瑞典)有限公司 针对αVβ6的抗体及其应用
EP2087008A1 (de) * 2006-10-19 2009-08-12 The Regents of the University of California BEHANDLUNG UND PRÄVENTION VON CHRONISCHEM ASTHMA MIT INTEGRIN-alphaVbeta6-ANTAGONISTEN
SI2182981T1 (sl) 2007-08-02 2013-05-31 Gilead Biologics, Inc. Postopki in sestavki za zdravljenje in diagnozo fibroze
KR101046317B1 (ko) * 2008-07-04 2011-07-05 이종대 조력발전 방법 및 그 장치
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
CN102481347A (zh) 2009-07-24 2012-05-30 加州大学董事会 治疗和预防整合素αvβ5相关疾病的方法及组合物
CA2771702A1 (en) 2009-08-21 2011-02-24 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and loxl2
RU2015124151A (ru) * 2009-08-21 2015-12-27 Джилид Байолоджикс, Инк. Способы и композиции для лечения фиброзных заболеваний легких
WO2011097513A1 (en) * 2010-02-04 2011-08-11 Gilead Biologics, Inc Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
WO2013123152A2 (en) 2012-02-17 2013-08-22 Seattle Genetics, Inc. ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
EP2784511A1 (de) 2013-03-27 2014-10-01 Universität Zürich Integrin-alpha-v-beta 6 zur Diagnose/Prognose von Kolorektalkarzinomen
JP6104312B2 (ja) * 2014-06-19 2017-03-29 日東電工株式会社 組織再生促進剤
JP7034914B2 (ja) * 2015-11-23 2022-03-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維症および／または線維性疾患の治療のための抗α－ｖインテグリン抗体
WO2019040608A1 (en) 2017-08-22 2019-02-28 Biogen Ma Inc. PHARMACEUTICAL COMPOSITIONS AND DOSAGE SCHEMES CONTAINING ANTI-ALPHA (V) BETA ANTIBODIES (6)
WO2021113697A1 (en) 2019-12-05 2021-06-10 Seagen Inc. Anti-avb6 antibodies and antibody-drug conjugates
IL297969A (en) * 2020-05-07 2023-01-01 Pliant Therapeutics Inc Treatment of respiratory diseases with amino acid compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5654270A (en) * 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
AU628910B2 (en) 1988-12-20 1992-09-24 La Jolla Cancer Research Foundation Polypeptide-polymer conjugates active in wound healing
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
ATE244306T1 (de) * 1994-12-20 2003-07-15 Merck Patent Gmbh Monoklonaler antikörper gegen das alpha-v- integrin
US20020004482A1 (en) * 1997-08-08 2002-01-10 Xiaozhu Huang Treatment of acute lung injury and fibrosis with antagonists of avbeta6

Also Published As

Publication number Publication date
RU2221589C2 (ru) 2004-01-20
WO1999007405A1 (en) 1999-02-18
TR200000374T2 (tr) 2000-09-21
IL134288A0 (en) 2001-04-30
EP1504764A1 (de) 2005-02-09
US20040208878A1 (en) 2004-10-21
US7150871B2 (en) 2006-12-19
EP1930022A1 (de) 2008-06-11
PT1504764E (pt) 2009-01-14
CZ2000413A3 (cs) 2000-11-15
US7544358B2 (en) 2009-06-09
PT1930022E (pt) 2011-08-01
KR100586202B1 (ko) 2006-06-07
NZ515955A (en) 2003-04-29
BR9814040A (pt) 2000-10-03
ATE410179T1 (de) 2008-10-15
AU8774398A (en) 1999-03-01
ATE511850T1 (de) 2011-06-15
EP1930022B1 (de) 2011-06-08
CA2297736A1 (en) 1999-02-18
CN1267224A (zh) 2000-09-20
EE04752B1 (et) 2006-12-15
IL134288A (en) 2008-07-08
HUP0003547A2 (hu) 2001-02-28
ES2235350T3 (es) 2005-07-01
DE69828614T2 (de) 2006-02-09
EE200000068A (et) 2000-10-16
ES2311131T3 (es) 2009-02-01
EP0996460B1 (de) 2005-01-12
CY1110462T1 (el) 2015-04-29
DK1930022T3 (da) 2011-07-25
CY1111792T1 (el) 2015-10-07
PT996460E (pt) 2005-04-29
PL199014B1 (pl) 2008-08-29
AU739283B2 (en) 2001-10-11
EP0996460A1 (de) 2000-05-03
EP1504764B1 (de) 2008-10-08
PL341029A1 (en) 2001-03-26
ES2364703T3 (es) 2011-09-12
CZ299768B6 (cs) 2008-11-19
JP2001513333A (ja) 2001-09-04
DE69828614D1 (de) 2005-02-17
EP0996460A4 (de) 2001-03-07
DE69840113D1 (de) 2008-11-20
NZ502546A (en) 2002-02-01
ATE286742T1 (de) 2005-01-15
US20020004482A1 (en) 2002-01-10
TR200202323T2 (tr) 2002-12-23
JP2009001587A (ja) 2009-01-08
US6692741B2 (en) 2004-02-17
US6316601B1 (en) 2001-11-13
HU228900B1 (en) 2013-06-28
HUP0003547A3 (en) 2002-05-28
US20010056076A1 (en) 2001-12-27
PL201716B1 (pl) 2009-05-29
US20070148173A1 (en) 2007-06-28
KR20010022740A (ko) 2001-03-26

Similar Documents

Publication Publication Date Title
DK1504764T3 (da) Behandling af leverfibrose med antistoffer mod alfa-V-beta-6-integrin
SI1007089T1 (sl) Antikoagulantska humanizirana protitelesa proti faktorju IX za uporabo pri zdravljenju tromboze
CY2010011I1 (el) Μορια αντισωματος που εμφανιζουν ειδικοτητα για ανθρωπινο παραγοντα νεκρωσης ογκων α, και χρηση αυτων
EE200300528A (et) Cripto valku blokeerivad antikehad ja nende kasutamine
CY2013010I1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
CY2009018I2 (el) Φαρμακευτικη συνθεση περιλαμβανουσα πιογλιταζονη και γλιμεπιριδη για χρηση στην θεραπεια του διαβητη
NO20002957L (no) Behandling med anti-ErbB2-antistoffer
ATE500815T1 (de) Neue suppositoriumsform mit säureempfindlichem wirkstoff
DE69840052D1 (de) Multikomponenten-partikel aus superabsorbierendem gel
DK1411064T3 (da) Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer
PL401886A1 (pl) Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
ATE334718T1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
CY2008019I2 (el) Υποκατεστημενες οξαζολιδινονες και η χρηση των στο πεδιο της πηξης αιματος
SG136804A1 (en) Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
DE69909168D1 (de) Wegwerfwindel mit Klebeverschlüssen
DE69940656D1 (de) Wegwerfwindel mit mechanischen Befestigungsmitteln
ATE336368T1 (de) Absorbierendes folienmaterial mit schnittfesten partikeln und verfahren zu dessen herstellung
EP1558284A4 (de) Kombinationstherapie mit klasse iii anticea monoklonalen antikörpern und therapeutischen wirkstoffen
DE60022930D1 (de) Wegwerfwindel mit elastischen dichten Rändern
DE69511148D1 (de) Wegwerfwindel mit verbessertem Abschluss an den Beinteilen
DE69832722D1 (de) L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen
ID21895A (id) Antibodi yang mengikat kepada grup laminin yang mengikat nidogen, pembuatannya dan penggunaannya
EP1013642A3 (de) Chelatoren sowie deren Tricarbonyl-Komplexe mit Technetium und Rhenium
ATE183069T1 (de) Wergwerfwindel mit taillenpolster
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen